{"id":"W4353088123","doi":"10.54097/hset.v36i.5576","title":"Single Drug Therapy of PD-1/PD-L1 Checkpoint Inhibitors for Advanced Urothelial Bladder Cancer","year":2023,"lang":"en","type":"article","venue":"Highlights in Science Engineering and Technology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"TD Bank Group","funders":"","keywords":"Pembrolizumab; Atezolizumab; Durvalumab; Medicine; Avelumab; Bladder cancer; Oncology; Immunotherapy; Internal medicine; Chemotherapy; Cancer; Lung cancer; Urothelial cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001926849,0.0001569461,0.0002875511,0.0008270809,0.00006929804,0.000009945265,0.0001468935,0.00009954721,0.000006813257],"category_scores_gemma":[0.00007650597,0.0001220674,0.00004072363,0.001640178,0.0003320636,0.00009141001,0.00005123015,0.0001102426,0.000006267727],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008917773,"about_ca_system_score_gemma":0.0001349944,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004802741,"about_ca_topic_score_gemma":0.00001510624,"domain_scores_codex":[0.9988006,0.000003487891,0.0002449844,0.0003688542,0.0001940566,0.000387957],"domain_scores_gemma":[0.9995206,0.00004094951,0.00005106751,0.0002287212,0.00009011869,0.00006851458],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001458655,0.0001397231,0.001807874,0.00006597595,0.00003971235,0.00001620913,0.0006277259,0.0004071941,0.9723452,0.004594258,0.0001712619,0.019639],"study_design_scores_gemma":[0.002701006,0.0004345703,0.002718052,0.0001626707,0.00001401733,0.00001083168,0.0001404168,0.00112675,0.9715495,0.0004877757,0.02048498,0.0001693982],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942764,0.0009778446,0.00008079132,0.003223837,0.0005398906,0.0004930072,0.00001823663,0.0002676883,0.0001222863],"genre_scores_gemma":[0.9969817,0.001132847,0.001310282,0.00002814317,0.00008292597,0.0002182592,0.00000214239,0.0000231488,0.0002205611],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02031372,"threshold_uncertainty_score":0.4977764,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01444287363552564,"score_gpt":0.2758400711814437,"score_spread":0.261397197545918,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}